MX2022008744A - Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. - Google Patents

Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.

Info

Publication number
MX2022008744A
MX2022008744A MX2022008744A MX2022008744A MX2022008744A MX 2022008744 A MX2022008744 A MX 2022008744A MX 2022008744 A MX2022008744 A MX 2022008744A MX 2022008744 A MX2022008744 A MX 2022008744A MX 2022008744 A MX2022008744 A MX 2022008744A
Authority
MX
Mexico
Prior art keywords
compounds
amino
acid ester
new
cancer compounds
Prior art date
Application number
MX2022008744A
Other languages
English (en)
Inventor
Christopher Mcguigan
Michaela Serpi
Hugh Griffith
Valentina Ferrari
Antunez Carmen Jimenez
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022008744(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1421211.2A external-priority patent/GB201421211D0/en
Priority claimed from GBGB1519316.2A external-priority patent/GB201519316D0/en
Application filed by NuCana plc filed Critical NuCana plc
Publication of MX2022008744A publication Critical patent/MX2022008744A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a compuestos químicos, los compuestos para usarse en un método de tratamiento, particularmente en un método de profilaxis o tratamiento para cáncer, un procedimiento para la preparación de los compuestos y composiciones farmacéuticas que comprenden los compuestos; los compuestos, en particular, pueden ser útiles en el tratamiento de leucemia, linfoma y/o tumores sólidos en homo sapiens; los compuestos son derivados de Cordicepina (3'-desoxiadenosina), que tiene una porción de éster fosforamidato de 2' y/o 5'-aminoácido.
MX2022008744A 2014-11-28 2017-05-26 Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. MX2022008744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1421211.2A GB201421211D0 (en) 2014-11-28 2014-11-28 Chemical compounds
GBGB1519316.2A GB201519316D0 (en) 2015-11-02 2015-11-02 Chemical compounds

Publications (1)

Publication Number Publication Date
MX2022008744A true MX2022008744A (es) 2022-07-27

Family

ID=54771155

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017006942A MX2017006942A (es) 2014-11-28 2015-11-27 Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX2020010375A MX2020010375A (es) 2014-11-28 2015-11-27 Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX2022008744A MX2022008744A (es) 2014-11-28 2017-05-26 Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017006942A MX2017006942A (es) 2014-11-28 2015-11-27 Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX2020010375A MX2020010375A (es) 2014-11-28 2015-11-27 Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.

Country Status (25)

Country Link
US (3) US10570168B2 (es)
EP (2) EP3683225A1 (es)
JP (2) JP6646668B2 (es)
KR (2) KR20230098915A (es)
CN (2) CN111909231A (es)
AU (2) AU2015352203B2 (es)
CA (1) CA2962373C (es)
CL (1) CL2017001336A1 (es)
CY (1) CY1122074T1 (es)
DK (1) DK3224268T3 (es)
EA (1) EA031727B1 (es)
ES (1) ES2742167T3 (es)
HR (1) HRP20191461T1 (es)
HU (1) HUE046850T2 (es)
IL (4) IL291927A (es)
LT (1) LT3224268T (es)
ME (1) ME03462B (es)
MX (3) MX2017006942A (es)
PH (1) PH12017500944A1 (es)
PL (1) PL3224268T3 (es)
PT (1) PT3224268T (es)
RS (1) RS59264B1 (es)
SG (2) SG10202009020VA (es)
SI (1) SI3224268T1 (es)
WO (1) WO2016083830A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2681227T3 (da) 2011-03-01 2016-02-22 Nucana Biomed Ltd Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
US10570168B2 (en) * 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CN110669088B (zh) * 2018-07-02 2023-03-28 成都阿奇生物医药科技有限公司 N-(2-乙基胺)苯磺酰胺基虫草素衍生物及其制备方法和应用
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN111888373A (zh) * 2019-05-05 2020-11-06 上海医药集团股份有限公司 一种虫草素或其药学上可接受的盐的应用
WO2023218202A2 (en) 2022-05-12 2023-11-16 NuCana plc Cancer treatment
CN115181148B (zh) * 2022-07-12 2023-07-14 南京工业大学 一种基于虫草素经衍生化具有抗肿瘤效应的化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2589935A1 (en) * 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
MA34471B1 (fr) 2010-07-19 2013-08-01 Gilead Sciences Inc Procédés de préparation de promédicaments au phosphoramidate pur au plan diastéréomère
US20120070411A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
DK2681227T3 (da) 2011-03-01 2016-02-22 Nucana Biomed Ltd Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
WO2013070887A1 (en) * 2011-11-10 2013-05-16 Inhibitex, Inc. Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
WO2015038596A1 (en) * 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CN107835687A (zh) 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
JP2017535587A (ja) 2017-11-30
MX2017006942A (es) 2017-08-24
JP6646668B2 (ja) 2020-02-14
AU2015352203B2 (en) 2019-08-15
EA031727B1 (ru) 2019-02-28
MX2020010375A (es) 2022-07-19
NZ767066A (en) 2022-03-25
CN107207554A (zh) 2017-09-26
IL276109B (en) 2022-05-01
AU2015352203A1 (en) 2017-04-27
NZ730919A (en) 2021-02-26
EP3224268A1 (en) 2017-10-04
HRP20191461T1 (hr) 2019-11-15
SG11201702369UA (en) 2017-04-27
US11352387B2 (en) 2022-06-07
IL251353A0 (en) 2017-05-29
DK3224268T3 (da) 2019-09-02
KR20230098915A (ko) 2023-07-04
CA2962373A1 (en) 2016-06-02
BR112017011187A2 (pt) 2018-01-02
PH12017500944A1 (en) 2017-11-20
CY1122074T1 (el) 2020-11-25
ME03462B (me) 2020-01-20
US10570168B2 (en) 2020-02-25
KR20170087465A (ko) 2017-07-28
EP3224268B1 (en) 2019-06-26
AU2019232929B2 (en) 2020-09-10
EP3683225A1 (en) 2020-07-22
SI3224268T1 (sl) 2019-10-30
CN111909231A (zh) 2020-11-10
WO2016083830A1 (en) 2016-06-02
PT3224268T (pt) 2019-09-04
CL2017001336A1 (es) 2017-12-15
IL292062A (en) 2022-06-01
CN107207554B (zh) 2020-09-11
IL292062B2 (en) 2023-06-01
LT3224268T (lt) 2019-09-25
US20170253629A1 (en) 2017-09-07
CA2962373C (en) 2023-04-25
JP2020075928A (ja) 2020-05-21
PL3224268T3 (pl) 2019-11-29
EA201791182A1 (ru) 2017-09-29
US20220306675A1 (en) 2022-09-29
IL291927A (en) 2022-06-01
JP6978524B2 (ja) 2021-12-08
HUE046850T2 (hu) 2020-03-30
IL276109A (en) 2020-08-31
RS59264B1 (sr) 2019-10-31
SG10202009020VA (en) 2020-10-29
AU2019232929A1 (en) 2019-10-10
ES2742167T3 (es) 2020-02-13
KR102548806B1 (ko) 2023-06-27
US20200181189A1 (en) 2020-06-11
IL251353B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2022008744A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
TN2017000357A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MX2017002852A (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
PH12017502002A1 (en) 5`-substituted nucleoside analogs
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
NZ730803A (en) Methods for the preparation of ribosides
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
PH12018502606A1 (en) Phosphoramidate nucleoside derivatives as anticancer agents
CR20200192A (es) Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos
WO2017059385A8 (en) 11,13-modified saxitoxins for the treatment of pain
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2015011779A (es) Nucleosidos biciclicos unidos en puente.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2018006155A (es) Una forma en estado solido de compuestos de pladienolida piridina y metodos de uso.
EP4292651A3 (en) Liponucleotide-based therapy for ards
CA3156667A1 (en) OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MY182134A (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and uses thereof
MX2017009608A (es) Compuestos anticancerigenos.
WO2017011559A8 (en) Compositions and methods for treating cancer